Originally published by our sister publication Clinical Oncology News
The FDA granted full approval to pembrolizumab (Keytruda, Merck), an anti–PD-1 (programmed death-1) therapy, for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors who have progressed following prior treatment and have no satisfactory alternative treatment options. 
The conversion from an